🔗 Share this article Social Media Content Creators Fueling Parallel Trade for Unlicensed Weight-Loss Medication A shadow market for unapproved weight-loss drugs is being driven by social media fitness personalities and vendors on messaging platforms, based on new investigations. Investigational Drug Acquiring Popularity Online The experimental drug, which remains in clinical trials, is being advertised by social media influencers for its supposed fat-burning properties. Viewers are urged to contact these profiles privately for source information, while also obtaining promotional offers. Active Trade on Social Networks Separately, a flourishing market exists on messaging services, where communities with thousands of participants share “before and after” images, administration instructions and claims of next-day UK delivery. Vendors market the drug there before redirecting customers to other platforms for transactions. Understanding The Experimental Drug Retatrutide is an investigational injectable developed by American pharmaceutical company Eli Lilly. The drug affects three intestinal hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Preliminary studies suggest it could assist individuals lose up to 25% of their body weight. Referred to as the “triple G”, the substance is being promoted online as the next Ozempic. Medical Experts Voice Concerns Nevertheless, doctors and pharmacists have cautions that the distribution of what is still an unapproved drug in the UK is a cause for concern and could result in users injecting products of uncertain source. Several experts said the popularity for retatrutide could be connected to the increasing cost of approved weight loss products such as Mounjaro. Legal Position and Implementation Selling the unapproved drug on social media or messaging apps is prohibited in the United Kingdom, as it is an unlicensed drug that cannot be marketed or distributed for human use under the British medical regulations. Several content creators try to sidestep the rules by calling to the substance as a “research chemical” or citing it as “not for human consumption”. The substance is not a controlled substance, but promotion and distribution can still violate medicines, advertising, and customer regulations, risking fines, legal action or prison. Service Response and Content Removal According to the social media company, the platform has taken down problematic content and prohibited related keywords and search suggestions. The company said it was dedicated to keeping the platform safe and investing in enhancing compliance measures. Online Trading Activities Investigations also discovered groups with up to 9,000 members marketing retatrutide using the platform's integrated search feature, which functions like a online catalog. Typing “retatrutide” immediately displays channels with thousands of users, populated with photos of weight loss, positive testimonials and detailed instructions for mixing or administering at residence. Within minutes of joining one group, a seller posted WhatsApp details, where most transactions take place. The vendor provided an instruction manual and guaranteed delivery within two days. When questioned whether the substance was authentic, one seller responded: “You can’t be sure.” Another provided a photo of a supposed testing documentation. None inquired about body mass, health issues or past usage. Product Information and Costs Inside these communities, messages display dark colored parcels with Royal Mail stickers, stating to include fresh supplies. One message stated: “It took eight of us to load them this morning.” Buyers can choose between dry substance containers, mixed at home with purified liquid, or ready-to-use injectors typically priced at £160 for 20 milligrams. When questioned how long a injector should be used, vendors give contradictory answers varying between a several days to “depends on your body”. Platform Oversight and Safety Measures A spokesperson for Telegram said it regularly moderated harmful material on its platform including material that promoted the “misuse of controlled medications”. The company added that it removed “millions of pieces of harmful content each day”. Medical Expert Cautions “People are administering materials they cannot confirm. Even if the research behind retatrutide is sound, these online versions may not contain what they claim,” stated a pharmacy expert, the director of pharmacy at Chemist4U. A medical professional of an online medical service linked the increase in interest to recent price rises for approved weight-loss drugs such as Mounjaro. “With costs increasing, patients are using social media. But counterfeit injections are highly dangerous. You cannot know what’s contained or whether the environment they were made in was clean,” she explained. Her staff has previously encountered individuals harmed by self-injection from unconfirmed suppliers. “We recognize the frustration, but buying from Telegram or communication platforms is taking chances with your well-being,” said Wyllie. “These substances could be contaminated or improperly measured.” Producer Position A representative from Eli Lilly stated retatrutide was in phase 3 research studies and had not been reviewed or approved by any government authority globally. “Therefore at this time no one can sell [it] for human use,” they said, noting that any product “falsely representing itself as a Lilly experimental product not yet authorized … may expose users to possibly significant health risks”.